Recent news and posts
Danish Health Technology Council updated evaluation methods and processes
The Danish Health Technology Council (Behandlingsrådet) launched in 2021 aimed to support the greater use of cost-effective technologies in the healthcare system through recommendations to regions and hospitals. The recommendations are not legally binding; however, it is expected that they will likely be followed and will impact funding decisions.
The Council develops two types of reports: evaluations and major analyses (større analyser). In both cases, there is a staged process: proposal, evaluation or analysis, decision, and implementation. However, there are some differences:
- The Council annually develops 2-3 ‘major analyses’ on the fundamental topics (e.g., treatment regimens, approaches to the organization of treatments) proposed by hospitals or regions (not industry);
- The Council annually prepares up to 15-25 ‘evaluations’ on marketed medical devices and health technologies proposed by any stakeholder (including industry).
In August 2023, the Council approved the changes in methods and processes for evaluations, which can now be based on completed HTAs from abroad:
- The Council will screen the latest HTAs from countries comparable to Denmark (such as Norway, Sweden, Finland, UK);
- It is planned that the list of proposed HTAs will be announced annually in the spring;
- The Council will evaluate selected HTAs within 5-8 months and provide recommendations considering the Danish context.
The Council has already selected the first four topics. However, the details of selected topics are not yet available.
See the full details in Danish here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.